This story is currently available in anglais only — a translation isn't ready yet.
MHRA launches women's health programme after trial data shows 1.1% pregnancy coverage
The regulator found pregnant women were represented in just 1.1% of UK clinical trial applications between 2019 and 2023, and breastfeeding women in 0.6%.
ℹ️ Lecture par le navigateur · voix studio IA bientôt
The Medicines and Healthcare products Regulatory Agency has launched a Women’s Health Programme running to 2030, aimed at closing evidence gaps on how the risks and benefits of medicines and medical devices may differ for women.
The MHRA said women make up 51% of the population but have historically been underrepresented in clinical research, limiting the evidence available on medicines and medical devices during pregnancy and across reproductive health. An MHRA analysis of all 4,616 UK clinical trial applications submitted between 2019 and 2023 found pregnant women were represented in just 1.1% of trials, while breastfeeding women were represented in 0.6%.
The programme will bring together patients, researchers, healthcare professionals and industry to strengthen the evidence available, the agency said, while maintaining its standards of safety, quality and effectiveness.
Women’s Health Minister Baroness Gillian Merron said: “For too long, women’s health has been overlooked.” She said the programme, together with the renewed Women’s Health Strategy, would mean “better evidence, better treatments”.
Lawrence Tallon, MHRA Chief Executive, said: “Better evidence can help us understand where important differences exist.”
The MHRA said the UK’s FemTech sector already has an annual turnover of nearly £300 million, with technologies being developed across areas from reproductive health to long-term conditions and healthy ageing.
Naho Yamazaki, Deputy Director of Policy and Partnerships at the Health Research Authority, said: “We welcome the MHRA’s Women’s Health Programme.” She pointed to joint MHRA and HRA guidance on developing an Inclusion and Diversity Plan as a practical framework for researchers.
Michelle Riddalls OBE, CEO of PAGB, The Consumer Healthcare Association, said: “It’s positive to see the MHRA’s new Women’s Health Programme.” She said better evidence could widen access to treatments through the reclassification of medicines, citing recent reclassifications of low-dose Estradiol vaginal products and Estriol cream that changed access to HRT for thousands of women.
The programme was shaped by patients, including through the MHRA’s Patient and Public Community and a focus group delivered by the Patients Association. The MHRA said it is the first part of a wider initiative to address health inequalities.